🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11117955

Anti-Zika virus antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117970

Human antibodies to PD-L1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11116839

Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein con

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11104715

Methods for producing aflibercept in chemically defined media having reduced aflibercept v

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11102961

Non-human animals having a humanized lymphocyte-activation gene 3

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11103552

High concentration VEGF receptor fusion protein containing formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11104729

Anti-IL-33 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11104730

Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098112

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098127

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098311

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084865

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11072656

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11071780

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacum

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066474

Anti-TrkB monoclonal antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11064685

Non-human animal models of retinoschisis

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066458

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11059896

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11051499

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053280

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053309

Methods for treating active eosinophilic esophagitis

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11045522

Glucagon-like peptide 1 receptor agonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034768

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11026997

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted